Cristina Cusin, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

12Articles
118KReads¹
2007–2026Active
92Collaborators
360Citations²

About

Cristina Cusin, MD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. Since 2007, Cusin has published extensively on major depressive disorder (MDD), exploring treatments such as ketamine, pramipexole, ziprasidone augmentation, and complementary approaches including omega-3 fatty acids and heated Hatha yoga. Her work also addresses clinical challenges in depression, including cognitive symptoms, treatment resistance, suicide ideation, and depression in postmenopausal women. Cusin frequently collaborates with Maurizio Fava, David Mischoulon, Dan V. Iosifescu, Dawn F. Ionescu, and Lauren B. Fisher.

Publications

Academic Highlights ▶ Video

Treatment-Resistant Depression as a Dynamic Continuum: A Consensus Panel Report

September 23, 2026

The panelists reframe treatment-resistant depression as a dynamic continuum and provide a four-stage framework that takes clinicians from initial detection through high-acuity interventions.

Anita H. Clayton, Michael Asbach, Patricia Cabrera, et al

Original Research

Heated Yoga for Depression

October 23, 2023

Approximately 1 heated yoga session per week for 8 weeks led to significantly greater reduction in depression symptoms than a waitlist control.

Maren B. Nyer, Lindsey B. Hopkins, Megha Nagaswami, et al

Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...

Anna Feeney, Bettina B. Hoeppner, Marlene P. Freeman, et al

Original Research

Omega-3 Fatty Acids for MDD With High Inflammation

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.

David Mischoulon, Boadie W. Dunlop, Becky Kinkead, et al

Original Research

Very Low-Level Transcranial Photobiomodulation for MDD

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...

Dan V. Iosifescu, Richard J. Norton, Umit Tural, et al

Original Research

Ganaxolone for Persistent Depression

June 9, 2020

Postmenopausal women may be deficient in the neuroactive steroid allopregnanolone. This study examined oral ganaxolone, an allopregnanolone analog, as augmentation therapy in postmenopausal women with inadequate response to traditional...

Laura E. Dichtel, Maren Nyer, Christina Dording, et al

Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...

Maurizio Fava, George I. Papakostas, Richard C. Shelton, et al

Letter to the Editor

Drs Ionescu and Cusin Reply

January 25, 2017

Cristina Cusin, Dawn F. Ionescu

Article

Ketamine for Suicidal Ideation

June 22, 2016

When your treatment-resistant depressed patients are thinking about suicide, what else can you as a clinician do to pull them from the brink of these ideations? Consider whether adjunctive...

David Mischoulon, Maurizio Fava, Lee Baer, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

July 15, 2013

Maurizio Fava, Andrew A. Nierenberg, Roy H. Perlis, et al

Rounds in the General Hospital

Complications of Carbon Monoxide Poisoning: A Case Discussion and Review of the Literature

April 16, 2009

Cristina Cusin, Theodore A. Stern, Christopher J. Hopwood, et al

Original Research

Early Symptomatic Worsening During Treatment With Fluoxetine in Major Depressive Disorder: Prevalence and Implications

January 15, 2007

Maurizio Fava, Jay D. Amsterdam, Frederick W. Reimherr, et al

¹ Read counts for articles published before 2020 may include some non-human traffic.

² Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Cristina Cusin, MD

About

Publications